At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 606 enrolled
Drug / intervention
Secukinumab (75 mg) +2 moredrug
Likely dose
Secukinumab (75 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis
In Brief
A Phase 3 clinical trial evaluating Secukinumab (75 mg), Secukinumab (150 mg), and 1 other intervention for Psoriatic Arthritis. Completed, enrolled 606 participants across 110 sites in 19 countries.
Detailed Summary
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Germany, Israel, Italy, Philippines, Poland, Romania, Russia, Singapore, Slovakia, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartSep 2011
Primary CompletionOct 2014
TodayJul 2026
First PostedJul 12, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.0 years ago
Interventions
Secukinumab (75 mg)drug
Secukinumab (75 mg)
Secukinumab (150 mg)drug
Secukinumab (150 mg)
Placebo Comparatordrug
Placebo Comparator